| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Molecular Cell Biology and Immunology, Vrige University University Medical Center, Amsterdam, The Netherlands;
Department of Parasitology, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands;
Department of Dermatology, Davis School of Medicine, University of California, Sacramento, CA; and
Department of Biochemistry and Molecular Biology, and Oklahoma Center for Medical Glycobiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1–4GlcNAc (LacNAc) moieties are the most common constituents of N-linked glycans on vertebrate proteins, GalNAc1–4GlcNAc (LacdiNAc, LDN)-containing glycans are widespread in invertebrates, such as helminths. We postulated that LDN might be a molecular pattern for recognition of helminth parasites by the immune system. Using LDN-based affinity chromatography and mass spectrometry, we have identified galectin-3 as the major LDN-binding protein in macrophages. By contrast, LDN binding was not observed with galectin-1. Surface plasmon resonance (SPR) analysis and a solid phase binding assay demonstrated that galectin-3 binds directly to neoglycoconjugates carrying LDN glycans. In addition, galectin-3 bound to Schistosoma mansoni soluble egg Ags and a mAb against the LDN glycan inhibited this binding, suggesting that LDN glycans within S. mansoni soluble egg Ags contribute to galectin-3 binding. Immunocytochemistry demonstrated high levels of galectin-3 in liver granulomas of S. mansoni-infected hamsters, and a colocalization of galectin-3 and LDN glycans was observed on the parasite eggshells. Finally, we demonstrate that galectin-3 can mediate recognition and phagocytosis of LDN-coated particles by macrophages. These findings provide evidence that LDN-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Because many pathogens exhibit foreign patterns of glycosylation, as compared with their vertebrate host, the resultant glycans constitute attractive candidates for immune recognition. Indeed, a number of lectins have been identified, including mannose-binding lectin, the macrophage mannose receptor (3), and the dendritic cell-associated C-type lectin dendritic cell-specific ICAM-3-grabbing nonintegrin (4, 5, 6), that recognize mannose- and/or fucose-containing ligands from viruses, bacteria, parasites, and/or fungi. Recently, it was demonstrated that dendritic cells recognize Gal1–4(Fuc
1–3)GlcNAc (Lewis-x (Lex), CD15) Ags on Schistosoma mansoni egg glycoproteins through interaction with dendritic cell-specific ICAM-3-grabbing nonintegrin (6). However, among helminth parasites, Lex Ags are restricted to certain species (7), whereas many helminths, including schistosomes, express GalNAc1–4GlcNAc (LacdiNAc (LDN)) glycans, or their fucosylated derivatives containing GalNAc1–4(Fuc1–3)GlcNAc (LDNF) (8, 9, 10, 11). LDN structures are abundant on the surfaces of worms and eggs, although the latter predominantly induce immune-mediated pathology (e.g., granuloma formation) during schistosomiasis (9). In addition, egg-derived Ags are potent immunogens and Abs against the LDN Ag have been detected in sera from infected human patients, mice, and primates (10, 12, 13).
Galectins (previously termed S-type lectins) constitute a family of mammalian -galactoside binding lectins (14, 15). Galectin-3 (MAC-2) is composed of a C-terminal carbohydrate recognition domain (CRD), that is responsible for -galactose recognition (16, 17), and an N-terminal domain consisting of multiple PGAYPG repeats, that mediates multimer formation (18). The structural basis for -galactose recognition by the galectin-3 CRD has been established by x-ray crystallography (17). Galectin-3 is synthesized and secreted by myeloid cells, including macrophages, as well as several other cell types (19, 20), and binds to a variety of endogenous glycoprotein ligands, including cell surface receptors and extracellular matrix proteins (21, 22). It has also been identified as an IgE-binding protein (23) and Abs to galectin-3 have been shown to inhibit IgE-mediated cytotoxicity of eosinophils to adult schistosomes (24). Thus far, there is no evidence for a direct role of galectin-3 in schistosome recognition.
We postulated that LDN may constitute a parasite pattern for recognition by the immune system and attempted to identify putative LDN-binding lectins in macrophages. The results demonstrate that galectin-3 constitutes a major macrophage LDN-binding protein that is highly expressed in granulomas and colocalizes with LDN on eggshells during S. mansoni infection, and that galectin-3 can mediate LDN recognition and phagocytosis by macrophages. This implicates LDN as a parasite pattern for galectin-3-mediated immune recognition.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Infection of golden hamsters with S. mansoni cercariae was performed as described previously (9). Animals were sacrificed after 7 wk and liver tissue was snap frozen in liquid nitrogen and stored at –80°C until further use. Male Wistar rats (6–12 wk of age) were obtained from Harlan/CPB (Horst, The Netherlands). Animals were maintained under conventional laboratory conditions allowing free access to food and water. Thioglycolate-elicited peritoneal macrophages were obtained by i.p. injection of 10 ml thioglycolate (Difco, Detroit, MI). After 4 days, the rats were sacrificed by CO2 inhalation and peritoneal cells were harvested by peritoneal lavage with Opti-MEM (Invitrogen Life Technologies, Carlsbad, CA) and subsequently stimulated overnight with 100 ng/ml LPS (Escherichia coli 055:B5; Difco) in RPMI 1640 medium (Invitrogen Life Technologies) containing 10% FCS (Invitrogen Life Technologies), 100 µg/ml streptomycin, and 100 U/ml penicillin. The THP-1 human monocytic cell line, and the NR8383 rat alveolar macrophage NR8383 cell line (25) were cultured in RPMI 1640 medium containing 10% FCS and antibiotics.
Abs, neoglycoconjugates, and lectins
The following Abs were used: the anti-galectin-3 mAb A1D6 (mouse IgG) (26), the anti-GalNAc1–4 (Fuc1–2 Fuc1–3) GlcNAc (LDN-DF) mAb 114-5B1-A (mouse IgG1) (9), the anti-LDN mAb SMLDN1.1 (mouse IgM) (10), the anti-LDN mAb 273-3F2 (mouse IgM) (9), and the anti-LDNF mAb SMLDNF1 (mouse IgM) (11). Enzymatically synthesized carboxymethyl octyl-Lex and LDN were coupled to BSA at similar molar ratios of 11–14 mol:mol as described (9). LacNAc (LN)-(CH2)3-NH2 was coupled to BSA at a molar ratio of 9 mol:mol via diethylsquarate according to the method described in Ref.27 . The polyvalent neoglycoconjugates LN-polyacrylamide (PAA) and LDN-PAA, were from Syntesome (Munich, Germany) (saccharide 20% mol). Digoxigenin-labeled Datura stramonium agglutinin (DSA) (DSA-dig) and peroxidase-labeled anti-dig Abs (anti-dig-PO) were from Boehringer Mannheim (Indianapolis, IN). PO-conjugated F(ab')2-fragments of goat anti-mouse IgM/IgG (GAM-PO) were from The Jackson Laboratory (Bar Harbor, ME).
Recombinant galectin-3 production
Strain BL21 (DE3) of E. coli was transformed with the rCPB30 plasmid encoding full-length hamster galectin-3 (28), and grown on Luria-Bertani agar containing 50 µg/ml ampicillin and 50 µg/ml chloramphenicol. Colonies were grown in Luria-Bertani medium for 2 days at 22°C; 0.4 mM isopropyl -D-thiogalactoside was added after 4 h of culture. Galectin-3 was isolated essentially according to Mehul et al. (26). Briefly, pelleted cells were resuspended in 20 ml/L culture of lysis buffer (1 M Tris-HCl pH 7.4, containing 1 mM EDTA, 10 mM 2-ME, and 1 mM PMSF). The samples were frozen and thawed twice and centrifuged. Proteins were precipitated using 65% ammonium sulfate for 16 h and centrifuged. The pellet was resuspended in 50 mM Tris-HCl pH 7.2, containing 150 mM NaCl, 1 mM EDTA, and 2 mM 2-ME, and dialyzed three times against buffer without 2-ME. Galectin-3 was purified on a 1-ml lactosyl-Sepharose 4B column as described (26), and eluted with 50 mM Tris-HCl pH 7.2, containing 150 mM lactose, 150 mM NaCl, 1 mM EDTA, and 2 mM 2-ME. Purity and identity were analyzed by 12.5% SDS-PAGE and silver staining, and Western blotting using anti-galectin-3 mAb A1D6 (28) and PO-conjugated rabbit anti-mouse (DakoCytomation, Carpinteria, CA), respectively. Galectin-3 was estimated to be at least 95% pure. Before use, lactose and 2-ME were removed using a Bio-Gel P4 column (Bio-Rad, Veenendaal, The Netherlands). Biotinylation of galectin-3 was conducted in the presence of lactose using NHS-LC-LC-biotin (Perbio Science, Etten-Leur, The Netherlands), according to manufacturer’s instructions.
Affinity purification and mass spectrometry of LN- and LDN-binding lectins
LN-(CH2)3-NH2 was treated with jackbean -galactosidase to remove the terminal galactose residue, and LDN was enzymatically synthesized using UDP-GalNAc and partially purified 4-N-acetylgalactosaminyltransferase from the albumen gland of Lymnea stagnalis as previously described (9). The structure was verified by 1H-nuclear magnetic resonance spectroscopy as described (29). LN-(CH2)3-NH2 and LDN-(CH2)3-NH2 (5 µmol each) were then covalently coupled to 1 ml HiTrap columns (Pharmacia, Peapack, NJ) according to the manufacturer’s instruction. NR8383 cells (109 total) and THP-1 cells (0.5 x 108 total) were washed, pelleted, and lysed by adding 3–4 ml of 50 mM Tris-HCl pH 7.2 buffer containing 1% Triton X-100, 150 mM NaCl, 2 mM CaCl2, and protease inhibitors, split, and passed over the LN and LDN columns. The columns were washed with 10 bed volumes of buffer and eluted with buffer containing 200 mM lactose or GalNAc, respectively. Samples were desalted, boiled in loading buffer and run on a reducing 15% SDS-PAGE. Proteins were visualized by silver or Coomassie brilliant blue staining. Indicated protein bands were excised and trypsinized, and extracted peptides were subjected to MALDI-TOF analysis as described (30).
SPR analysis
The Lex-, LN-, and LDN-BSA conjugates were used to generate a Biacore sensor chip (Stevenage, U.K.) as described in detail (12). Briefly, the neoglycoproteins were immobilized at a flow rate of 5 µl/ml in 10 mM sodium-acetate pH 4.0 onto a carboxymethylated dextran CM5 sensor chip (Biacore) by covalent amine coupling until an increase in 
4000 response units was observed. All analyses were performed using a Biacore 3000 instrument at a flow rate of 5 µl/ml at 25°C using 50 mM Tris-HCl pH 7.2 buffer containing 150 mM NaCl, 1 mM EDTA, and 2 mM 2-ME. Galectin-3 was injected at concentrations from 0 to 10 µM, and where indicated, 150 mM lactose was added to the samples. Injection times of samples were 2 min, followed by buffer injection to allow dissociation. The sensor chips were regenerated using a 2-min pulse of 100 mM HCl.
Solid phase binding assay
The solid phase binding assay was performed by coating neoglycoconjugates (0.1 µg/ml) or S. mansoni soluble egg Ags (SEA) (5 µg/ml) in ELISA plates overnight at 4°C, followed by blocking with 1% nonfat dried milk (Nutricia, The Netherlands) in TBS (50 mM Tris-HCl pH 7.4 containing 200 mM NaCl) for 30' at room temperature (RT). After washing with TBS/0.1% Tween 20, biotinylated recombinant galectin-3 (1 µg/ml in TBS/0.1% Tween 20) was added, and the adhesion was performed for 60 min at RT. Unbound galectin-3 was washed away and binding was determined by streptavidin-PO conjugate. LDN glycans were detected with anti-LDN (mAb SMLDN1.1) and GAM-PO. DSA-dig was detected with anti-dig-PO. Where indicated, anti-glycan mAbs were used as competitive inhibitors. After blocking, coated SEA were preincubated with anti-glycan mAbs (SMLDN1.1, SMLDNF1, at concentration 0.1 mg/ml) for 30' at RT before adding galectin-3. Coating of the neoglycoconjugates and SEA was confirmed in all experiments with appropriate lectins and glycan-specific Abs.
Immunohistochemistry
Immunohistochemistry was performed as previously described (31). Briefly, acetone-fixed cryostat sections (5 µm) were incubated with 10 µg/ml anti-galectin-3 mAb A1D6 in PBS containing 0.1% BSA (PBS/BSA). After washing, sections were incubated with Alexa594-conjugated GAM Ig in PBS/BSA containing 1% hamster serum. Access binding sites were then blocked with 20% normal mouse serum, and the sections were incubated with 10 µg/ml anti-LDN mAb 273-3F2 (mouse IgM (9)), washed, and subsequently incubated with FITC-conjugated F(ab')2 rabbit anti-mouse IgM in the presence of 1% hamster serum. The sections were then mounted in Fluorostab (Cappel) and evaluated on a Nikon Eclipse E800 fluorescence microscope (Melville, NY).
Phagocytosis assay
Hundred microliters of a 1% suspension of carboxylated green fluorescent beads (0.75 µM; Polysciences, Warringtion, PA) were incubated with 25 µg LDN-BSA overnight at 4°C on a rollerbank. Coated beads (0.00125%) were preincubated with 50 µg/ml galectin-3 in Opti-MEM containing 0.1% BSA for 30' on ice; where indicated, 150 mM lactose was added. The beads were then added to washed LPS-stimulated thioglycolate-elicited peritoneal macrophages and incubated for 1 h at 37°C. After washing in PBS, the macrophages were detached using 4% lidocaine in PBS/BSA and phagocytosis was measured by flow cytometry using a FACScan (BD Biosciences, San Jose, CA). The percent of phagocytosis was calculated from the mean fluorescence intensity of macrophages incubated with beads minus the mean fluorescence intensity of macrophages incubated without beads, and normalized to 100% using values obtained from macrophages incubated with BSA-coated beads.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To identify putative LDN-binding lectins, macrophage lysates from rat NR8383 and human THP-1 macrophage cell lines were passed over an affinity column containing immobilized LDN. Samples were passed over a control column with immobilized LN in parallel. Bound proteins were eluted with lactose, separated by SDS-PAGE, and visualized by silver staining (Fig. 1). Each cell type yielded a unique pattern of retained proteins. A major 35-kDa protein bound to both LN and LDN was present in NR8383 cell lysates, whereas a major 14-kDa protein bound to LN but not LDN in the THP-1 lysates. The major 35-kDa LDN-binding protein from NR8383 cells was excised from gel and trypsinized, and a selected peptide was subjected to mass spectrometric fragmentation. This yielded the peptide sequence GNDIAFHFNPR that corresponds to rat galectin-3 (23). The 14-kDa protein from THP-1 lysates bound by LN was identified by mass spectrometric fingerprinting as human galectin-1. Taken together, these results demonstrate that galectin-3 constitutes the major LDN-binding lectin in NR8383 macrophages, whereas galectin-1 does not bind LDN-glycans.
|
To confirm that galectin-3 binds directly to LDN we analyzed the binding of purified recombinant hamster galectin-3 to LDN and to other related glycans by SPR using neoglycoconjugates. For proper comparison, the Biacore channels were coated with similar amounts of BSA-glycoconjugates in a molar glycan:BSA ratio of 10–12 mol:mol. This demonstrated that galectin-3 binds both to LN and LDN at all concentrations tested (1–10 µM, Fig. 2, and results not shown). However, a proper analysis of affinity was hampered because of the known oligomerization of galectin-3 (18). Binding of galectin-3 to BSA-LDN was completely prevented in the presence of 150 mM lactose, supporting involvement of the -galactoside-binding CRD in LDN recognition. Consistent with previous findings (32), no binding to immobilized-BSA-Lex was observed, thus demonstrating the strong negative influence of 1–3 fucosylation of the GlcNAc moiety on galectin-3 recognition. There was no detectable binding to the BSA-coated channel (data not shown).
|
|
The SEA, which include LDN glycan Ags, constitute major antigenic determinants during S. mansoni infection (8, 34). Furthermore, granuloma formation around eggs depends on T cell-mediated immunity directed against such Ags (35). Importantly, recent findings in galectin-3-deficient mice indicate a supportive role for galectin-3 in granuloma formation (M. C. El-Cheikh, C. Takiya, and R. Chammas, personal communication). Therefore, it was of interest to investigate whether galectin-3, which can form multimers via its N-terminal repeats (18), facilitates the binding and uptake of LDN-containing glycoconjugates by APCs, such as macrophages. Activated rat peritoneal macrophages were incubated with fluorescent latex beads coated with BSA-LDN, with and without addition of galectin-3. The uptake of BSA-LDN beads was significantly enhanced as compared with control BSA beads, in particular when exogenous galectin-3 was added (Fig. 4). By contrast, the phagocytosis of control BSA-coated beads that also was observed was not enhanced by addition of exogenous galectin-3. The uptake of BSA-LDN beads could be prevented to the level seen with BSA-coated beads by adding lactose (data not shown). It should be noted that the enhanced binding of BSA-LDN beads as compared with control beads, even in the absence of exogenous galectin-3, is in line with the expression of endogenous surface galectin-3 on activated macrophages (results not shown, see also Ref.36). These results demonstrate that galectin-3 can act as an opsonin to facilitate the uptake of LDN-containing glycoconjugates by leukocytes and as such can mediate parasite-host cell interactions.
|
A possible interaction between galectin-3 and LDN glycans, the latter of which are expressed on the surface of worms and eggs shells during S. mansoni infection (9), was studied by double staining of livers of infected hamsters using mAbs against galectin-3 and LDN. In livers from healthy animals, a constitutive expression of galectin-3 was observed in sinusoidal lining cells (Fig. 5, a–c). In infected animals, high levels of galectin-3 were found in the granulomas surrounding eggs (Fig. 5, d–f) and worms (Fig. 5, g–i). In addition, galectin-3 colocalized with LDN expressed on the surface of eggs. Colocalization of LDN Ags and galectin-3 was also observed on the surfaces of worms, although the galectin-3 staining was less intense on the worm surface than on eggs.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Liver granuloma formation during S. mansoni infection is a major cause of pathology and is generally considered to be mainly the result of a T cell-mediated immunological reaction against parasite eggs (34, 37). The recent observation that granuloma formation during S. mansoni infection is significantly reduced in galectin-3-deficient mice (M. C. El-Cheikh, C. Takiya, R. Chammas, personal communication) provides direct evidence for a role of galectin-3 during parasite infection in vivo and suggests that galectin-3 plays a supportive role in granuloma formation. Clearly, more investigation is necessary to understand the exact role of galectin-3 in granuloma formation during schistosome infection. One possibility that is supported by our current evidence is that multimeric galectin-3 facilitates the uptake and presentation of LDN-containing Ags by macrophages (and/or other APCs). This uptake may trigger a more pronounced T cell response against the parasite, that may in turn promote granuloma formation. That a specific immune response against LDN-containing Ags does indeed occur during schistosomiasis is supported by the observation that Abs to LDN are present during experimental infection and in patients (10, 12, 13). Furthermore, soluble egg Ags have been detected in macrophages during S. mansoni infection (38). It will be interesting to evaluate cellular and humoral immune responses against soluble egg Ags during schistosomiasis in galectin-3-deficient mice.
It should be noted that recent evidence suggests that other schistosome-derived glycans, such as the difucosylated LDN-related oligosaccharide LDN-DF (39) and LeX-containing glycoconjugates (5, 40), may also act as PAMPs to modulate macrophage cytokine production and dendritic cell maturation. However, the strict requirement for fucose in these studies points to recognition by different (i.e., galectin-unrelated) lectin-like receptors. Taken together, it seems likely that during helminth parasite infection different glycans, including LDN, contribute to pathogen recognition and the development of host immunity.
Although most galectins recognize LN moieties (32), the recognition of LDN glycans by a member of the galectin family has not been reported to our knowledge. The observation that lactose competes for LDN binding to galectin-3 indicates that LDN recognition involves the galectin-3 CRD. The inability of galectin-1 to recognize LDN as apparent from the affinity chromatography (Fig. 1) as well as from preliminary SPR experiments (C.H.H. and R.D.C, unpublished observations) demonstrates that LDN recognition is not a general property of galectin family members. The structural basis for binding of galactose by the galectin-1 and galectin-3 CRDs have been resolved by x-ray crystallography (41, 17), and this may provide a rational explanation for the observed difference in specificity between galectin-1 and -3. Indeed, our preliminary evaluation of these structures suggests that galectin-3 can accommodate the O-2 N-acetyl moiety of the GalNAc residue, while a bulky histidine (at position 52) in galectin-1 may prevent GalNac binding. Obviously, the exact structural explanation needs further investigation, but it seems clear, at least, that LDN binding is not common to all galectin family members. One interesting possibility is that galectin-3, by adopting LDN-binding activity during evolution, provided the innate immune system with a sensor for parasitic helminth infection, and likewise its host, with a selective evolutionary advantage.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
1 This work was supported in part by National Institutes of Health Grant AI047214 (to R.D.C.). 
2 Address correspondence and reprint requests to Dr. Timo K. van den Berg, Department of Molecular Cell Biology and Immunology, Vrige University University Medical Center, FdG Postbus 7057, 1007 MB Amsterdam, The Netherlands. E-mail address: t.vandenberg{at}vumc.nl
3 Abbreviations used in this paper: PAMP, pathogen-associated molecular pattern; CRD, C-terminal carbohydrate recognition domain; dig, digoxigenin; DSA, Datura stramonium agglutinin; GAM, goat anti-mouse; Lex, Lewis-x; LN, LacNAc; LDN, LacdiNAc; LDNF, GalNAc1–4(Fuc1–3)GlcNAc; LDN-DF, GalNAc1–4 (Fuc1–2 Fuc1–3) GlcNAc; PAA, polyacrylamide; PO, peroxidase; RT, room temperature; SEA, Schistosoma mansoni soluble egg Ag; SPR, surface plasmon resonance.
Received for publication February 25, 2004. Accepted for publication May 19, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1–4 (Fuc1–3) GlcNAc and GalNAc1–4 (Fuc1–2Fuc1–3) GlcNAc carbohydrate epitopes: detection with monoclonal antibodies that are characterized by enzymatically synthesized neoglycoproteins. Glycobiology 10:601.1–4GlcNAc) determinants. Glycobiology 9:1029.-galactoside-binding lectins. Cell 76:597.[Medline]
BP) expressed by human eosinophils: implication in IgE-dependent eosinophil cytotoxicity. Eur. J. Immunol. 23:3230.[Medline]
3-fucosyltransferase and a novel 2-fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: biosynthesis of the Fuc1–2Fuc1–3[Gal(NAc)1–4]GlcNAc sequence. Glycobiology 8:393.1,4GlcNAc1,3] sequences in asparagine-linked oligosaccharides of the mouse lymphoma cell lines BW5147 and PHAR2.1. J. Biol. Chem. 259:6253.1–4(Fuc1–2Fuc1–3)GlcNAc. J. Infect. Dis. 185:531.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. G. Shainheit, P. M. Smith, L. E. Bazzone, A. C. Wang, L. I. Rutitzky, and M. J. Stadecker Dendritic Cell IL-23 and IL-1 Production in Response to Schistosome Eggs Induces Th17 Cells in a Mouse Strain Prone to Severe Immunopathology J. Immunol., December 15, 2008; 181(12): 8559 - 8567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, M. Komai-Koma, D. S. Gilchrist, D. K. Hsu, F.-T. Liu, T. Springall, and D. Xu Galectin-3 Is a Negative Regulator of Lipopolysaccharide-Mediated Inflammation J. Immunol., August 15, 2008; 181(4): 2781 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Rapoport, S. Andre, O. V Kurmyshkina, T. V Pochechueva, V. V Severov, G. V Pazynina, H.-J Gabius, and N. V Bovin Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: A case study on galectins-1 and -3 and the impact of assay setting Glycobiology, April 1, 2008; 18(4): 315 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yoon, A. Terada, and H. Kita CD66b Regulates Adhesion and Activation of Human Eosinophils J. Immunol., December 15, 2007; 179(12): 8454 - 8462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Breuilh, F. Vanhoutte, J. Fontaine, C. M. W. van Stijn, I. Tillie-Leblond, M. Capron, C. Faveeuw, T. Jouault, I. van Die, P. Gosset, et al. Galectin-3 Modulates Immune and Inflammatory Responses during Helminthic Infection: Impact of Galectin-3 Deficiency on the Functions of Dendritic Cells Infect. Immun., November 1, 2007; 75(11): 5148 - 5157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jang-Lee, R. S. Curwen, P. D. Ashton, B. Tissot, W. Mathieson, M. Panico, A. Dell, R. A. Wilson, and S. M. Haslam Glycomics Analysis of Schistosoma mansoni Egg and Cercarial Secretions Mol. Cell. Proteomics, September 1, 2007; 6(9): 1485 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tasumi and G. R. Vasta A Galectin of Unique Domain Organization from Hemocytes of the Eastern Oyster (Crassostrea virginica) Is a Receptor for the Protistan Parasite Perkinsus marinus J. Immunol., September 1, 2007; 179(5): 3086 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Oliveira, P. Frazao, R. Chammas, D. K. Hsu, F. T. Liu, R. Borojevic, C. M. Takiya, and M. C. El-Cheikh Kinetics of mobilization and differentiation of lymphohematopoietic cells during experimental murine schistosomiasis in galectin-3 / mice J. Leukoc. Biol., August 1, 2007; 82(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Harvie, T. W. Jordan, and A. C. La Flamme Differential Liver Protein Expression during Schistosomiasis Infect. Immun., February 1, 2007; 75(2): 736 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jouault, M. El Abed-El Behi, M. Martinez-Esparza, L. Breuilh, P.-A. Trinel, M. Chamaillard, F. Trottein, and D. Poulain Specific Recognition of Candida albicans by Macrophages Requires Galectin-3 to Discriminate Saccharomyces cerevisiae and Needs Association with TLR2 for Signaling J. Immunol., October 1, 2006; 177(7): 4679 - 4687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kohatsu, D. K. Hsu, A. G. Jegalian, F.-T. Liu, and L. G. Baum Galectin-3 Induces Death of Candida Species Expressing Specific beta-1,2-Linked Mannans J. Immunol., October 1, 2006; 177(7): 4718 - 4726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wuhrer, C. A. M. Koeleman, J. M. Fitzpatrick, K. F. Hoffmann, A. M. Deelder, and C. H. Hokke Gender-specific expression of complex-type N-glycans in schistosomes Glycobiology, October 1, 2006; 16(10): 991 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Van de Vijver, A. M. Deelder, W. Jacobs, E. A. Van Marck, and C. H. Hokke LacdiNAc- and LacNAc-containing glycans induce granulomas in an in vivo model for schistosome egg-induced hepatic granuloma formation Glycobiology, March 1, 2006; 16(3): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nieminen, C. St-Pierre, and S. Sato Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses J. Leukoc. Biol., November 1, 2005; 78(5): 1127 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. van Vliet, E. van Liempt, E. Saeland, C. A. Aarnoudse, B. Appelmelk, T. Irimura, T. B. H. Geijtenbeek, O. Blixt, R. Alvarez, I. van Die, et al. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells Int. Immunol., May 1, 2005; 17(5): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. S. Kawar, S. M. Haslam, H. R. Morris, A. Dell, and R. D. Cummings Novel Poly-GalNAc{beta}1-4GlcNAc (LacdiNAc) and Fucosylated Poly-LacdiNAc N-Glycans from Mammalian Cells Expressing {beta}1,4-N-Acetylgalactosaminyltransferase and {alpha}1,3-Fucosyltransferase J. Biol. Chem., April 1, 2005; 280(13): 12810 - 12819. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
